Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115301 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von M Wislez und 18 weiteren Autor:innen. Beteiligte Einrichtung: APHP, Hôpital Cochin, Service de Pneumologie, Unité d'Oncologie Thoracique, Paris, France; Université Paris Cité, Paris, France. Electronic address: …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APHP, Hôpital Cochin, Service de Pneumologie, Unité d'Oncologie Thoracique, Paris, France; Université Paris Cité, Paris, France. Electronic address: marie.wislez@aphp.fr.
- CHU de Strasbourg, Nouvel Hôpital Civil, Service de Pneumologie, Pôle de Pathologie Thoracique, Strasbourg, France.
- APHP, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique, Paris, France; GRC04, Theranoscan Sorbonne Université, Paris, France.
- Institut du cancer de Montpellier, Service d'Oncologie Médicale, Montpellier, France.
- Université de Rennes 1, Unité COSS INSERM U1242 - CEM, Rennes, France; CHU Rennes, Service de Pneumologie, Rennes, France.
- Centre Léon Bérard, Department of Medical Oncology, Lyon, France.
Förderung
- Amgen Inc
Zitieren
APA
Wislez, M., Mascaux, C., Cadranel, J., Thomas, Q. D., Ricordel, C., Swalduz, A., Pichon, E., Veillon, R., Gounant, V., Rousseau-Bussac, G., Madroszyk, A., Daniel, C., Ravoire, M., Metivier, A. C., Fournel, P., Missy, P., Morin, F., Guisier, F., & Westeel, V. (2025). Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115301
Vancouver
Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, et al. Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115301
BibTeX
@article{Wislez2025,
author = {Wislez, M and Mascaux, C and Cadranel, J and Thomas, Q D and Ricordel, C and Swalduz, A and Pichon, E and Veillon, R and Gounant, V and Rousseau-Bussac, G and Madroszyk, A and Daniel, C and Ravoire, M and Metivier, A-C and Fournel, P and Missy, P and Morin, F and Guisier, F and Westeel, V},
title = {Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115301}
}
EUVIMED